ODAC Recommends Approval of First Biosimilar Drug
The Oncologic Drugs
Advisory Committee (ODAC) of the Food and Drug Administration (FDA) recommended
the approval of the first application for a biosimilar drug on January 7. The panel recommended that FDA approve the
application for a biologic agent similar to filgrastim. This drug would be used for a number of
applications in hematology.
Medicare Begins Paying for Chronic Care Management
On January 1, 2015,
the Medicare program took a significant step towards recognizing that the role
of a physician goes well beyond time in the exam room. For the first time, Medicare will begin
paying physicians for chronic care management. ASH is pleased that Medicare is finally paying for this service, but still has concerns over the coding and billing requirements. Read more to learn how this could affect hematology.
Highlights from the 2014 APP Lunch
The ASH Practice Partnership (APP) hosted its annual luncheon event at the 2014 ASH Annual Meeting in San Francisco on Sunday, December 7. This year's topic was "Whither the Practice of Hematology in an Era of Mergers?" Read more to hear about the speakers and presentation.
SGR – Where Do We Go from Here?
As the 113
Congress winds down, it has become clear that this group of legislators will not be remembered as the one that permanently addressed the issues associated with Medicare physician payment. Read more to find out what may happen with the SGR in 2015.